Pharmaceuticals, Biotechnology and Life Sciences
Superbug bacteria found in people, animals and food across the European Union pose an “alarming” threat to public and animal health having evolved to resist widely used antibiotics, disease and safety experts warned on Wednesday.
A UK-based private clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, has triggered the phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of the dry eye syndrome.
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.
Bayer has reported net income of €4,531 million which is 10.2% increase comparing to 2015 (€4,110 million). The company reported earnings growth in pharmaceutical activities, while other activities remain steady.
Arix Bioscience’s issued ordinary shares have on Wednesday been admitted to the Official List of the UK Listing Authority and to trading on the London Stock Exchange’s main market for listed securities under the ticker “ARIX”.
Advanced Oncotherapy, the developer of next generation proton therapy systems for cancer treatment, has secured a flexible and staged £26 million financing agreement with Bracknor Investment Group, a Dubai-based investment firm.
Amgen on Tuesday got clearance from the European Commission (EC) for a new single-dose delivery option for its Repatha cardiovascular drug.
Following a diet that mimics fasting may reduce risk factors for disease in generally healthy people, according to a small study.
Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Ireland’s Valeant Pharmaceuticals for the distribution of Ammonul injection, an acute Urea Cycle Disorders (UCDs) drug, in Europe, the Middle East and North Africa.
Nicox, the international ophthalmic R&D company has presented preclinical results from its novel nitric oxide (NO) donating compound, NCX 667 at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy.